Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
SHELTON, Conn., March 03, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, March 10, 2016, at 4:30 p.m. ET to report fourth quarter and full year 2015 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 56780146. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
